Choosing New Therapies for Gonorrhoea: We Need to Consider the Impact on the Pan-<i>Neisseria</i> Genome. A Viewpoint
The development of new gonorrhoea treatment guidelines typically considers the resistance-inducing effect of the treatment only on <i>Neisseria gonorrhoeae</i>. Antimicrobial resistance in <i>N. gonorrhoeae</i> has, however, frequently first emerged in commensal <i>Neis...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
MDPI AG,
2021-05-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The development of new gonorrhoea treatment guidelines typically considers the resistance-inducing effect of the treatment only on <i>Neisseria gonorrhoeae</i>. Antimicrobial resistance in <i>N. gonorrhoeae</i> has, however, frequently first emerged in commensal <i>Neisseria</i> species and then been passed on to <i>N. gonorrhoeae</i> via transformation. This creates the rationale for considering the effect of gonococcal therapies on resistance in commensal <i>Neisseria</i>. We illustrate the benefits of this pan-<i>Neisseria</i> strategy by evaluating three contemporary treatment options for <i>N. gonorrhoeae</i>-ceftriaxone plus azithromycin, monotherapy with ceftriaxone and zoliflodacin. |
|---|---|
| Item Description: | 10.3390/antibiotics10050515 2079-6382 |